We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

GE Healthcare and BAC Announce Collaboration

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

GE Healthcare, a unit of General Electric Company and BAC BV, the Bio Affinity Company, have announced that they have entered into a strategic collaboration in the affinity ligand and chromatographic media area.  

Under the terms of the agreement, the two companies will develop affinity chromatography media for human antibodies and adeno-associated virus (AAV) viral vector purification.

The first products are expected to be commercially available during 2007 through GE Healthcare’s Custom Designed Media business. 

The collaboration is expected to generate several affinity chromatography media solutions for biopharmaceutical manufacture and drug discovery research.

"This collaboration will allow us to expand our current range of ligand technologies and libraries, enabling us to develop more efficient purification processes for our customers in biopharmaceutical manufacturing," said Ann O’Hara, General Manager of BioProcess for GE Healthcare.

"As a well established market leader, GE Healthcare is the perfect partner for us," said Dr. Laurens Sierkstra, CEO of BAC. 

"This Agreement underlines their confidence in our  CaptureSelect® products and clearly validates our technology as a giant step forward in the purification of pharmaceutical products."